BAUSCH HEALTH COS INC
BHCNYSEUS Equity
$172.85▼ $10.04 (−5.81%)
Simulated price1h—
24h▼ 5.8%
7d—
14d—
30d—
1y—
🏦Market Cap
$233.49B
Large Cap
📈Revenue Growth (YoY)
+8.2%
Slowing
📊Gross Margin
71.0%
High
💵FCF Margin
9.4%
Moderate
⚖️P/S Ratio
0.2x
Cheap
Otter Score
45
Weak
No chart data available for BHC.
Trading Snapshot
- Day Range
- $171.24 – $174.15
- 52-Week Range
- $6.10 – $11.97
- Volume
- $2.80B
- Avg Volume
- $2.10B
- Shares Outstanding
- 373.5M
- Next Earnings
- Oct 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $18.53B
- Last Q Revenue
- $4.97B
- P/E Ratio
- —
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-3.24
- Dividend Yield
- —
Why Investors Own BHC
- ✓High-growth profile — revenue up +2.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$18.53B▲ +3.0% YoY
Gross Margin (TTM)
69.5%▲ +1.2% YoY
Operating Income (TTM)
$4.54B▲ +3.0% YoY
Free Cash Flow (TTM)
$3.11B▲ +3.0% YoY
About BAUSCH HEALTH COS INC
A company profile for BAUSCH HEALTH COS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
45/100
Analyst Price Target
ⓘAverage Target
$169.31
▼ −2.0% Downside
High Target$197.25
Low Target$127.73
Based on 29 analysts
Latest News & Updates
🚀
Reuters·2h ago
BAUSCH HEALTH COS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift BHC price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
BAUSCH HEALTH COS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.